Master Alliance Provisions Guide (MAPGuide)

Gates Foundation – CureVac, Global Access Commitments Agreement

  • Equitable Access | Affordable pricing

<p>“<strong>Access Countriesstrong>” means the countries (each anAccess Country”) on the World Bank list of lowincome and lower middleincome economies (<a href=””_blankrel=”noopener“> [external link]a>) on the Effective Date, which are set forth on Appendix 2. If after the Effective Date a country which was an Access Country on the Effective Date (i) is removed from such list and (ii) if such country becomes part of the European Union or is subject to another treaty with other nonAccess Countries which leads to a material increase of the risk of parallel imports, the Parties will cooperate in good faith to reasonably reduce the risk of parallel imports and if it is not possible to reduce the risk to a degree that is acceptable to both Parties, such country will be removed from the list of Access Countries for purposes of this Agreement.p>
<p>“<b>Access Country Dosesb>” means vaccines and drugs the Company has developed using funds from the Foundation or Foundationsupported Entities in connection with Projects and that are intended for use in the Access Countries (including, without limitation, vaccines and drugs for use in clinical trials).p>
<p><span style=”textdecoration: underline;”><b>3. Global Access Commitmentsb>span>p>
<p><b>(a) Vaccine and Drug Development Projectsb>p>
<p>(i) The Company will work together with the Foundation on all stages of vaccine and drug development and commercialization for Target Diseases and Conditions. Each Project will be documented in a definitive agreement between the Foundation or a Foundationsupported Entity which Project is chosen by the Foundation and approved by the Company (such approval not to be unreasonably withheld or delayed) for such Project and the Company and a project plan (each a “<em><strong>Projectstrong>em>”), which may include work to be undertaken, responsibilities, participation by other parties, timelines and milestones, project management, contributions inkind and funding requirements, a product development and marketing plan, product registration in the Access Countries, any additional global access commitments specific to the Project, terms for manufacturing and commercialization of Access Country Doses and the price for Access Country Doses, which must be an affordable price for sales for use in the Access Countries that the Parties agree will not exceed [*****]. The Company will permit the Foundation or a representative designated by the Foundation to reasonably inspect twice every [*****] during regular business hours and at the Foundations cost the Companys books and records as well as manufacturing documentation (including but not limited to the detailed bill of materials) for the purpose of determining cost of goods sold for each Product.p>
<p>(iv) The Company further agrees that it will not reject any Projects proposed by the Foundation unless the Company can demonstrate that accepting such Project would be reasonably likely to have a material adverse effect on the Company (“<b><i>Good Reasoni>b>”). By way of example, the Company agrees that it will not constitute Good Reason for the Company to reject a Project because the Company could make a higher profit by performing other work, but the Company will not be required to accept a Project on terms that would cause the Company to operate at a loss without any offsetting benefit.p>